Reuters logo
BRIEF-Novo Nordisk says Xultophy demonstrates similar glucose control to insulin glargine
December 2, 2016 / 8:25 AM / in a year

BRIEF-Novo Nordisk says Xultophy demonstrates similar glucose control to insulin glargine

Dec 2 (Reuters) - Novo Nordisk

* Says Xultophy (IDegLira) demonstrates similar glucose control with reduced risk of hypoglycaemia and a superior weight profile compared to basal-bolus therapy

* Says the trial successfully achieved its objective by demonstrating that treatment with Xultophy is non-inferior to insulin glargine U100 in combination with insulin aspart with regards to lowering of HbA1c

* Says people treated with Xultophy showed a superior reduction of 89 percent in the rate of severe or blood glucose confirmed symptomatic hypoglycaemic episodes compared to insulin glargine u100 in combination with insulin aspart

* Says from a mean baseline body weight of 87.7 kg, people treated with Xultophy experienced weight loss of 0.9 kg compared with weight gain of 2.6 kg for people treated with the basal-bolus regimen; a superior weight difference of -3.6 kg

* Results are from phase 3b trial DUAL VII

Further company coverage: (Reporting by Copenhagen Newsroom; editing by Jason Neely)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below